US 11,723,956 B2
Immunomodulation after locoregional anti-tumoral treatment
Robert Malafosse, Paris (FR); Nathalie Mignet, Clamart (FR); Vincent Boudy, Paris (FR); Johanne Seguin, Kremlin Bicetre (FR); Kathia Lemdani, Paris (FR); and Claude Capron, Boulogne (FR)
Assigned to Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Université de Paris, Paris (FR); Assistance Publique—Hopitaux de Paris, Paris (FR); Ecole Nationale Superieure de Chimie de Paris, Paris (FR); and Universite de Versailles—St. Quentin en Yvelines, Versailles (FR)
Appl. No. 16/327,543
Filed by Institut National de la Sante et de la Recherche Medicale (INSERM), Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); UNIVERSITÉ DE PARIS, Paris (FR); Assistance Publique—Hopitaux de Paris, Paris (FR); Ecole Nationale Superieure de Chimie de Paris, Paris (FR); and Universite de Versailles—St Quentin en Yvelines, Versailles (FR)
PCT Filed Aug. 31, 2017, PCT No. PCT/EP2017/071924
§ 371(c)(1), (2) Date Feb. 22, 2019,
PCT Pub. No. WO2018/041981, PCT Pub. Date Mar. 8, 2018.
Claims priority of application No. 16306102 (EP), filed on Aug. 31, 2016; and application No. 17305558 (EP), filed on May 16, 2017.
Prior Publication US 2019/0201492 A1, Jul. 4, 2019
Int. Cl. A61K 38/19 (2006.01); A61K 39/07 (2006.01); A61K 41/00 (2020.01); A61K 47/10 (2017.01); A61K 47/36 (2006.01); A61P 35/00 (2006.01); A61K 47/34 (2017.01); A61K 9/00 (2006.01); A61K 39/04 (2006.01); A61K 9/06 (2006.01); C07K 16/28 (2006.01); A61K 31/765 (2006.01); A61K 39/395 (2006.01); A61K 38/38 (2006.01); A61K 39/00 (2006.01)
CPC A61K 38/193 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (2013.01); A61K 31/765 (2013.01); A61K 38/385 (2013.01); A61K 39/04 (2013.01); A61K 39/07 (2013.01); A61K 39/39541 (2013.01); A61K 41/0028 (2013.01); A61K 41/0052 (2013.01); A61K 47/10 (2013.01); A61K 47/34 (2013.01); A61K 47/36 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/522 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/585 (2013.01); A61K 2039/82 (2018.08); C07K 2317/76 (2013.01)] 13 Claims
 
1. A thermosensitive mucoadhesive polymeric hydrogel comprising:
at least one thermosensitive copolymer, consisting of poloxamer 407 at a concentration of 21% w/v, in one aqueous solution; and
xantham gum at a concentration of 0.1% w/v;
wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and at least one cytokine and/or at least one chemokine and/or at least one heat shock protein, and wherein said hydrogel presents a gelification temperature between 21° C. and 28° C., and can be administered as a flowable liquid but will gelify on the tissue of interest.